14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AKAN vs VRAX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AKAN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–3 Matrix Metrics)
AKAN Overall Winner
6-Pillar Tally: AKAN 3 – 2 VRAX (1 Tie)
Matrix Metrics: AKAN 4 – 3 VRAX
As of Nov 20, 2026, Akanda Corp. Common Shares (AKAN) is the stronger overall head-to-head candidate over Virax Biolabs Group Limited (VRAX) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AKAN carries a Unified Composite Score of 39.8/100 (SELL) at $4.23 (N/M Forward P/E, -1254.5% operating margin), whereas VRAX carries 46.5/100 (HOLD) at $0.33 (N/M Forward P/E, -51515.2% operating margin).
Composite vs. Pillar Nuance: While VRAX currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. AKAN 39.8/100 SELL), AKAN captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-1254.5% vs. -51515.2% operating margin) and revenue trajectory (+21.9% vs. +684.9% YoY).
Technical & Structure Timing Caution: AKAN is currently in a Breakdown options structure phase (RSI 75.2); meanwhile VRAX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKAN vs VRAX. Trailing 12-month operating profitability (AKAN -1254.5% vs VRAX -51515.2%) and valuation multiples (AKAN N/M vs VRAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $470,745 market capitalization and -51515.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AKAN vs VRAX Key Questions & Quantitative Answers
As of Nov 20, 2026, Akanda Corp. Common Shares (AKAN) is the stronger overall head-to-head candidate over Virax Biolabs Group Limited (VRAX) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AKAN carries a Unified Composite Score of 39.8/100 (SELL) at $4.23 (N/M Forward P/E, -1254.5% operating margin), whereas VRAX carries 46.5/100 (HOLD) at $0.33 (N/M Forward P/E, -51515.2% operating margin). Composite vs. Pillar Nuance: While VRAX currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. AKAN 39.8/100 SELL), AKAN captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-1254.5% vs. -51515.2% operating margin) and revenue trajectory (+21.9% vs. +684.9% YoY). Technical & Structure Timing Caution: AKAN is currently in a Breakdown options structure phase (RSI 75.2); meanwhile VRAX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VRAX leads the Growth & Scale pillar: AKAN posts +21.9% YoY revenue growth and +0.0% YoY earnings growth on $662,469 TTM revenue (-12.0% gross margin, -1254.5% operating margin), compared with VRAX at +684.9% YoY revenue growth and +0.0% YoY earnings growth on $12,423 TTM revenue (61.9% gross margin, -51515.2% operating margin). On trailing 12-month operating scale, AKAN generates $662,469 in USD-normalized revenue versus $12,423 for VRAX. In operating R&D and SG&A reinvestment, AKAN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VRAX.
AKAN screens cheaper on headline valuation multiples. AKAN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.5x EV/Revenue (unreported EBITDA margin), whereas VRAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKAN (-60.9% ROE) versus VRAX (-78.6% ROE) capital efficiency.
In options market volatility and institutional positioning, AKAN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (4.82β · 524% Vol realized risk). By comparison, VRAX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-8.20β · 162% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.